Clinical Trial

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-07; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2026-04-14
Trial Details
NCT Number NCT07054099
Lead Sponsor GC Biopharma Corp
Conditions Varicella (Chickenpox), Chickenpox Vaccine
Enrollment 474 participants
Start Date 2026-03-17
Primary Completion 2027-08 (estimated)
Study Completion 2036-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-17